key: cord-0987023-p9pkuvlw
authors: Piper-Vallillo, Andrew J.; Halbert, Brian T.; Rangachari, Deepa; Kobayashi, Susumu S.; Costa, Daniel B.
title: Acquired resistance to osimertinib plus savolitinib is mediated by MET-D1228 and Y1230 mutations in EGFR mutated MET amplified lung cancer
date: 2020-06-20
journal: JTO clinical and research reports
DOI: 10.1016/j.jtocrr.2020.100071
sha: af348d9a14c33a4f830ce1958240f48e515a6760
doc_id: 987023
cord_uid: p9pkuvlw

nan

MET proto-oncogene, receptor tyrosine kinase (MET) gene amplification is an established mechanism of acquired resistance to all classes of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR mutated lung cancer. Novel strategies to target EGFR mutated MET amplified tumors in clinical trials have shown promise, with clear activity of the combination of osimertinib and savolitinib reported from the TATTON trial (NCT02143466) in 2020. 1 Savolitinib is a type IB selective MET kinase inhibitor, in the same class as capmatinib and tepotinib (Table 1 ). 2, 3 There is a paucity of data on mechanisms of acquired resistance to combination osimertinib and savolitinib. Herein, we report a case of EGFR mutated and MET amplified lung adenocarcinoma that developed resistance to combination osimertinib and savolitinib due to MET-dependent mechanisms. The clinical, genomic, radiographic and retrospective outcome data used for this case report have been compiled under an ongoing institutional review board-approved protocol at our institution with appropriate waiver of consent.

A 61-year-old Asian man with a prior 5 pack-year history of smoking initially presented with early stage node-positive lung adenocarcinoma. After initial management with lobectomy and adjuvant platinum-doublet chemotherapy, he developed within one year widespread metastatic recurrence harboring EGFR delL747_T751 mutation. He was treated with erlotinib orally (PO) daily for 14 months before developing disease progression in his liver. Targeted biopsy revealed metastatic lung adenocarcinoma with EGFR-delL747_T751 (exon 19 deletion) and MET amplification (FoundationOne, Foundation Medicine). The MET:centrome_probe_SE7 ratio was 7.73 (cMET FISH Kreatech assay, Integrated Genetics, LabCorp), confirming high level amplification.

Suspecting MET amplification as the mechanism of resistance to the EGFR TKI, he was transitioned to osimertinib 80mg PO daily in combination with savolitinib 300mg PO daily under clinical trial TATTON 1 on which he achieved partial response for 18 months before developing progressive disease ( Figure 1 ). Tissue biopsy confirmed adenocarcinoma and next-generation sequencing of circulating tumor DNA (FoundationOne Liquid, Foundation Medicine) disclosed EGFR-delL747_T751 mutation (allele frequency [AF] 3.3%), lack of EGFR-T790M or EGFR-C797S, MET amplification and MET mutations (D1228H AF 15.6%, D1228N AF 1.8%, D1228Y AF 1.6%, Y1230C AF 0.98%). Off-label cabozantinib 60mg PO daily was added to osimertinib 80mg PO daily in an effort to target these MET mutations (Table 1) . Although he achieved stable disease (Figure 1 ), he developed significant fatigue, gastrointestinal toxicity, and cytopenias on dual inhibitor therapy; requiring cessation of cabozantinib. A repeat liquid biopsy disclosed the original truncal EGFR mutation, MET amplification and the known MET-D1228X mutations ( Figure 1 ). He continued on osimertinib, but passed away three months later.

MET amplification is a commonly observed (5-20% of cases) mechanism of resistance to EGFR TKIs. The EGFR plus MET co-inhibition strategy of osimertinib plus savolitinib is undergoing final regulatory approval for EGFR mutated plus MET amplified advanced lung cancer in the SAVANNAH trial (NCT03778229). Resistance to combined EGFR and MET inhibition is poorly understood, but can be expected to occur should this strategy gain wide appeal. Our report highlights MET-dependent resistance mechanisms (rather than EGFRdependent mechanisms) mediated by MET kinase mutations in a similar pattern seen in one prior case report. 5 Single agent savolitinib has been associated with MET-D1228X and Y1230X resistance mutations in other MET amplified tumor types. 6 Cabozantinib is a multikinase type II MET kinase inhibitor with putative preclinical activity against type I MET inhibitor resistance mutations, including MET-D1228X and Y1230X activation loop mutations (Table 1) , 4,5 and offers a potential treatment strategy as seen in a prior case treated with erlotinib 100mg PO daily plus cabozantinib 60mg PO daily 5 ; but has significant toxicity that may limit widespread combinatory use as seen in our case report. Understanding the true frequency of MET mutations as a mechanism of resistance to osimertinib plus savolitinib will help define the need to develop novel MET inhibitors with broader activity against MET mutations and additional therapies to delay or prevent the heterogeneity of on-target and off-target resistance to EGFR TKIs. Ia  crizotinib  sensitive  resistant  resistant  resistant  resistant  resistant  Ib  savolitinib  sensitive  resistant  resistant  resistant  resistant  resistant  Ib  capmatinib  sensitive  resistant  resistant  -resistant  resistant  II  cabozantinib  sensitive  -sensitive  sensitive  -sensitive  II  glesatinib  sensitive  sensitive  sensitive  -sensitive Fig.1 

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models

Structural and Molecular Insight into Resistance Mechanisms of First Generation cMET Inhibitors

Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer

Acquired MET D1228V Mutation and Resistance to MET Inhibition in Lung Cancer

Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer